WHIPPANY, N.J., April 29, 2019 /PRNewswire/ — Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review to darolutamide for the treatment of non-metastatic…Original Article
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
